Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director or Manager (PDMR), rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It contains specific transaction details for a single event:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Type: Acquisition of Ordinary Shares via dividend re-investment.
- Transaction Date: July 14, 2016.
- Price: £16.5875 per share.
- Volume: 344 shares.
- Location: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It solely discloses a routine share acquisition by a PCA (Mr. I W Whyte) following the dividend payment date of July 14, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- Verify the identity of the PCA (Mr. I W Whyte) and their relationship to the Company Secretary (Mrs. V A Whyte).
- Confirm the share price of £16.5875 aligns with market data for July 14, 2016.
- Note that this filing does not reflect the company's overall financial performance for the period.